Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Gene transference

DRUG CLASS:

Gene transference

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab + aglatimagene besadenovec Sensitive: B - Late Trials pembrolizumab + aglatimagene besadenovec Sensitive : B	pembrolizumab + aglatimagene besadenovec Sensitive: B - Late Trials pembrolizumab + aglatimagene besadenovec Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	aglatimagene besadenovec Sensitive: B - Late Trials aglatimagene besadenovec Sensitive : B	aglatimagene besadenovec Sensitive: B - Late Trials aglatimagene besadenovec Sensitive : B
MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3
MGMT promoter methylation	Glioma	MGMT promoter methylation	Glioma	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	aglatimagene besadenovec Sensitive: C3 – Early Trials aglatimagene besadenovec Sensitive : C3	aglatimagene besadenovec Sensitive: C3 – Early Trials aglatimagene besadenovec Sensitive : C3
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	aglatimagene besadenovec Sensitive: C3 – Early Trials aglatimagene besadenovec Sensitive : C3	aglatimagene besadenovec Sensitive: C3 – Early Trials aglatimagene besadenovec Sensitive : C3
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D